Skip to main content
Premium Trial:

Request an Annual Quote

VIMRX, Columbia Univ. Agree to Collaborate on New Cancer Targets

Premium

WILMINGTON, Del.--Bioinformatics will be used to develop diagnostic and therapeutic targets under terms of a new agreement between VIMRX Pharmaceuticals here and Columbia University. The development work will be based on two cancer genes, recently identified by scientists at the Columbia Genome Center, that control non-Hodgkin's lymphoma and multiple myeloma.

The agreement grants VIMRX Genomics, a subsidiary of the pharmaceutical company, the rights to the gene licenses and patents developed through the partnership. A spokeswoman for VIMRX said Columbia's four-person bioinformatics team will be used in the target development efforts. "To enhance the commercial potential of these important genes, VIMRX will seek technology strategic alliances with pharmaceutical and/or diagnostic companies to develop a cancer gene package that includes the identified and validated gene target, functional assays, and candidate diagnostic or therapeutic molecules," commented Richard Kouri, president of VIMRX.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.